Although TKIs have not been proven to cure CML, people who have an excellent response to TKI therapy have expectations for survival that are similar to age-matched individuals without CML. Available TKIs include imatinib (brand name: Gleevec), nilotinib (brand name: Tasigna), dasatinib (brand ...
Analysis of survival of CML patients in the last 15 years in LebanonCoelacanthLatimeria menadoensisTranscriptomede novo assemblyRNA-seqABSTRACTdoi:10.1016/j.clml.2015.07.075Massoud, M.Sakr, R.Kerbage, F.Makdissi, J.Hawi, J.Nasr, F.Chahine, G....
浙江大学博士学位论文CML酪氨酸激酶抑制剂分子靶向药物及异基因造血干细胞移植分层治疗研究姓名:***学位级别:博士专业:内科学(血液病学)指导教师:**20120518浙江大学博士学位论文中文摘要CML酪氨酸激酶抑制剂分子靶向药物及异基因造血干细胞移植分层治疗研究浙江大学医学部博士研究生导师内科学(血液病学)罗依黄河教授中文...
Following the chronic phase, an accelerated phase, sometimes called transformation can occur, with the development of a rapidly increasing number of blasts in the peripheral circulation. Once this occurs, survival is normally between 2 and 6 months. How is Chronic Myeloid Leukaemia Treated? The exac...
imatinib doses had higher and faster response rates in the first year of treatment, but by 42 months the high- and low-dose arms showed similar rates of major molecular response (MMR) and no differences in event-free survival (EFS), progression-free survival (PFS), or overall survival (...
ABL mutations in late chronic phase chronic myeloid leukemia patients with up-front cytogenetic resistance to imatinib are associated with a greater likelihood of progression to blast crisis and shorter survival: a study by the GIMEMA Working Party on Chronic Myeloid Leukemia. J Clin Oncol 2005; 23...
The Sokal index predicts survivalbased characteristics such as the patient’s age, spleen size on clinical examination, platelet count, and percentage of blasts in the peripheral blood. Depending on the Sokal score, patients are classified as having low-risk, intermediate-risk, or highrisk CML, ...
Improved survival was seen in those patients transplanted within12 months of diagnosis and in those less than 40 years of age.No survival advantage could be attributed to any specific methodof pretransplant marrow preparation or to the use of peripheralblood rather than bone marrow as a source of...
The median age was 53 years (range 18鈥 86). Ten out of 215 patients (5%) had a high EUTOS score. The median follow-up was 43 months (range 18鈥 69 months). We analyzed: the rates of Complete Cytogenetic Response (CCyR) and Major Molecular Response (MMR); the...
Life expectancy with CMR 4 and 4.5 was identical to that of the age matched population. We conclude that dose optimized IM induces CMR 4.5 faster than IM 400 and that CMR 4 and CMR 4.5 at 3 years are associated with a survival advantage. Dose optimized IM may provide an improved ...